Please login to the form below

Not currently logged in
Email:
Password:

Novaliq GmbH appoints Friedrich von Bolen as chairman

And Gerald Cagle joins as a member of the supervisory board

Heidelberg-based Novaliq has named Friedrich von Bolen as chairman of its supervisory board, which Gerald Cagle also joins as a board member.

Dr von Bolen, co-founder of dievini Hopp Bio Tech and Lion Bioscience AG, brings to the role 20 years of entrepreneurial experience and has been active in the life sciences industry since 1997.

He currently serves on several of the dievini portfolio's supervisory boards and has been chairman of Lion Bioscience's board since 2004.

Novaliq's chief executive officer and managing director Bernard Günther said: “We are pleased to have Friedrich join Novaliq as the chairman of our supervisory board.

His 20 years of entrepreneurial experience is of great importance for the further prosperity of the company and especially in building a successful specialty pharma company focusing on ophthalmology.”

Prior to his appointment as a board member of Novaliq, Dr Cagle was senior vice president of Alcon R&D and chief scientific officer from 1996 to mid-2008 having worked as a member of Alcon's research and development team for over thirty years.

He has since worked on the management of Alzheimer's disease and serves on the boards of Aerie Pharmaceuticals, Clearside Biomedical, AB2 and GrayBug.

Dr von Bohlen, new chairman of the supervisory board, said: “Gerald's broad business and R&D background in this industry is an important contribution and will be crucial for Novaliq with regard to the evaluation and development of highly effective ocular therapeutics.” 

7th January 2016

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...

Latest intelligence

New from the PhRMA: Diversity in clinical trials principles summarised
In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
New from the FDA: Diversity in clinical trials guidance summarised
In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....
5 steps to effective clinical trial branding
When recruiting patients for your clinical trial, you want the materials and information around it to be seen as reputable and professional. To make it clear what the clinical trial...

Infographics